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The objectives of this study were to determine prevalence of sickle cell disease 
(SCD) in a Medicaid population, to determine all-cause health care resource utilization 
and incremental health care resource utilization associated with SCD.  An observational 
database analysis was conducted using information from a large administrative claims 
database.  Individuals continuously enrolled in a tracked health plan during the period 
from January 1, 2012 through December 31, 2012, were eligible for inclusion in the 
sample for determination of SCD prevalence.  To select the sample for estimating all-
cause resource utilization and incremental resource utilization associated with SCD, 
administrative claims and enrollment records from January 1, 2012 through December 
31, 2012 were examined to select 8,652 individuals with SCD based on ICD-9-CM 
diagnosis codes.  SCD patients were linked one-to-one on age, gender, and race with 
individuals without SCD resulting in 8,652 persons in the comparison group and a total 
of 17,304 persons in the overall sample.  The number of individuals enrolled anytime 
during the period from January 1, 2012 through December 31, 2012 that had a diagnosis 
for SCD, were identified and divided by the total population of covered individuals 




resource utilization among individuals with SCD were estimated by counting the total 
number of hospitalizations, hospital days, outpatient visits, and emergency room visits.  
Incremental health care resource utilization associated with SCD was estimated using 
regression models adjusting for risk factors including age, gender, and race, 
comorbidities, and Medicare coverage status.   
The prevalence of SCD was one in 594 persons or 1,684 cases per million people.  
Ninety-five percent confidence interval was estimated to be 1,649 to 1,720 cases per 
million people. 
Mean annual hospitalizations among individuals with SCD were 1.39 (95 percent 
C.I.: 1.3 to 1.4) as compared to 0.10 (95 percent C.I.: 0.09 to 0.1) hospitalizations in 
persons without SCD.  Mean annual hospital days among individuals with SCD were 
7.04 (95 percent C.I.: 6.68 to 7.40) as compared to 0.50 (95 percent C.I.: 0.42 to 0.59) 
hospital days in persons without SCD.  Mean annual outpatient visits in individuals with 
SCD were 24.7 (95 percent C.I.: 23.9 to 25.5) as compared to 14.18 (95 percent C.I.: 13.4 
to 14.9) outpatient visits in persons without SCD.  Mean annual emergency room visits in 
individuals with SCD were 3.71 (95 percent C.I.: 3.5 to 3.9) as compared to 0.89 (95 
percent C.I.: 0.8 to 0.9) emergency room visits in persons without SCD.     
Incremental hospitalizations among individuals with SCD were 1.38 (S.E.: 0.05, 
p<0.001), whereas incremental hospital days among individuals with SCD were 6.94 
(S.E.: 0.29, p<0.001).  Incremental outpatient visits among individuals with SCD were 
7.27 (S.E.: 0.37, p<0.001), and incremental emergency room visits among individuals 




Among 8,652 persons with SCD, 4,972 had a diagnosis of Sickle Cell Crisis and 
3,680 persons with SCD had no diagnosis of Sickle Cell Crisis.  Mean annual 
hospitalizations among individuals with Sickle Cell Crisis were 2.17 (95 percent C.I.: 
2.08 to 2.25) as compared to 0.34 (95 percent C.I.: 0.31 to 0.38) hospitalizations in 
persons without Sickle Cell Crisis.  Mean annual hospital days among individuals with 
Sickle Cell Crisis were 10.98 (95 percent C.I.: 10.41 to 11.54) as compared to 1.72 (95 
percent C.I.: 1.47 to 1.98) hospital days in persons without Sickle Cell Crisis.  Mean 
annual outpatient visits among individuals with Sickle Cell Crisis were 26.12 (95 percent 
C.I.: 25.14 to 27.10) as compared to 22.91 (95 percent C.I.: 21.46 to 24.35) outpatient 
visits in persons without Sickle Cell Crisis.  Mean annual emergency room visits among 
individuals with Sickle Cell Crisis were 5.28 (95 percent C.I.: 4.97 to 5.60) as compared 
to 1.58 (95 percent C.I.: 1.45 to 1.72) emergency room visits in persons without Sickle 
Cell Crisis.   
In conclusion, SCD was associated with considerable incremental health care 
resource utilization as compared to individuals without SCD.   Additionally, persons with 
SCD and Sickle Cell Crisis had significant higher healthcare resource utilizations as 









Sickle Cell Disease 
 
Sickle Cell Disease (SCD) is a group of monogenic disorders that results in 
misshapen red blood cells (G. R Sergeant 2013).  At the molecular level, SCD is the 
result of mutation on single protein substrate where the ‘sixth amino acid residue of the 
β-globin chain leading to replacement of a negatively charged glutamic acid for a 
hydrophobic valine residue (M.H. Steinberg 1998).’  While anemia and frequent fatigue 
associated with sickled shape of red blood cells are common occurrences in persons with 
SCD, broad phenotypic variation observed in the manifestations of SCD that vary from 
being completely free of any sickle cell symptoms to complex secondary complications 
involving more than one organ system, progressing invariably and causing irreversible 
organ damage. 
Although progress has been made in treating SCD, interventions are primarily 
focused on managing symptoms of SCD.  In an absence of any available cure, at present, 
the treatment paradigm for sickle cell disease can be only described as evolving.  While 
few clinical trials of new agents are in progress, many clinical trials have failed.  With the 




episodes, and prophylactic penicillin for prevention of pneumococcal disease in children, 
controlled clinical trials have not established the superiority of any treatment modality.  
Therefore, overall mortality rate in early age has declined across past fifty years, (S. 
Sheth, M. Licursi, and M. Bhatia 2013), resultant health care utilization associated with 
SCD continues to rise.  
Literature Review 
Types of SCD 
 
The most common types of SCD are sickle cell anemia, sickle hemoglobin C 
disease, sickle β+ thalassemia, and sickle β-zero thalassemia.  People inheriting two 
sickle cell genes (S), suffer from sickle cell anemia.  Sickle cell anemia (HbSS) is most 
prevalent genotype among SCD.  People inheriting sickle cell gene (S) and (C) from each 
parent have sickle hemoglobin C disease (HbSC).  Sickle hemoglobin C disease is a 
milder form of SCD compared to sickle cell anemia but more prone to proliferative sickle 
retinopathy. 
People inheriting S gene and beta thalassemia gene, suffer from sickle β 
thalassemia.  There are two types of beta thalassemia: sickle β-zero thalassemia and β+.  
Those with β-zero thalassemia have a relatively more severe type of SCD as compared to 
people with HbS β+ genes (G. R. Serjeant 2013).  
Some rare types of SCD include HbD, HbE and HbO based on D, E or O genes 
inherited from parents in addition to sickle-S gene. The severity of these rarer types of 




have Sickle Cell trait.  Compared to individuals with SCD, individuals with Sickle Cell 
Trait exhibit no complications of SCD (G. R. Serjeant 2013). 
Clinical Manifestations of Sickle Cell Disease 
 
Sickle cell disease and its complications are multifold ranging from affecting a 
blood vessel to multiple organ failure.  Prominent complications of SCD include Vaso-
occlusive crisis, priapism, splenic sequestration, stroke, and organ damage (O.S. Platt et 
al. 1991).  
Vaso-Occlusive Crisis 
 
Painful crisis episodes in SCD individuals are the most common clinical events 
(O.S. Platt et al. 1994).  Majority of the painful episodes are not preceded by any 
indicators.  In some patients it is difficult to distinguish among new episodes of acute 
pain, chronic pain with acute exacerbations, therapy induced pain, and pain made worse 
by major psychosocial issues.  Vaso-occlusive crisis is the phenomenon leading to 
blockage of blood vessels clinically exhibited as pain at the tips of hands and legs, 
involving abdomen and back in certain cases and lasts for two or more hours.  The pain is 
characteristic to SCD, unexplained otherwise (O. S. Platt et al. 1991).  The most common 
location of a vaso-occlusion crisis is identified to be bone.  A rhythmical trend in 
occurrence of painful crisis show peak pain between 2pm to 9pm and a drop in pain 
levels around early morning at 5am”(S. E. Auvil-Novak, R. D. Novak, and N. el Sanadi 
1996).  Factors known to trigger sickle cell crisis include lower temperatures, increased 
hemoglobin density, lack of water in the body, improper diet, or emotional instability (O. 




of age have an approximate zero to three sickle cell crisis events per year.  With an 
increase in age, increase in crisis events is also noted.  Authors also note that no relation 
was observed between occurrence of a painful crisis and consequent mortality in 
individuals below twenty years of age.  
Ballas, 1995 identified four distinct phases of vaso-occlusive crisis (S. K. Ballas 
1995).  Ballas observed that the first phase termed as prodromal phase, included aches, 
numbness in extremities, and occurrence of paresthesia was reported by approximately 
sixty percent of individuals with SCD, a day prior to the start of crisis related pain.   
The first stage of sickle cell crisis includes symptoms such as fever, lack of 
appetite, and moderate anxiety.  Symptoms in the infarctive stage include increase in 
RBC cell density, and decrease in platelets count.   
Continuous and severe pain marks the presence of the final stage of crisis that 
varies from four to five days at an average.  Other prominent symptoms include, 
increased intra-articular fluid in joints leading to join pain, swelling, redness and elevated 
body temperature.  Clinical indicators of the final stage of crisis include higher levels of 
lactate dehydrogenase and C-reactive protein along with decrease in hemoglobin content 
of the blood.   
Resolving stage of crisis is marked with noticeable decrease in pain and lasts one 
to two days at an average.  C-reactive protein levels and hemoglobin levels return back to 
steady state by the end of the resolving stage.  Ballas & Smith indicate an increase in 
blood thickness, and sticky molecules of blood, as the primary cause for triggering 




Sequestrations & Priapism 
 
Priapism is an occurrence of a sustained and painful penile erection without any 
related sexual stimuli that can last for hours and can lead to nausea, fatigue as well as 
SCD specific pain”(M. H. Steinberg 1998).     
Sequestration is a common occurrence in persons with SCD primarily due to rigid 
shaped sickled blood cell obstructing the blood vessels and resulting in distending of 
organs (M. H. Steinberg 1998).  Consequent reduced blood flow is exhibited clinically as 
intense unbearable pain resulting from asphyxiation of tissue neighboring blocked blood 
vessels.  While sequestration is fairly uncommon in individuals above the age of five 
years, it can critically lower hemoglobin concentrations, lead to organ rupture, and is 
occasionally fatal (M. H. Steinberg 1998).  
Stroke 
 
Stroke due to sickled shaped red blood cell occluding blood vessels in persons 
with SCD is usually fatal (G. R. Serjeant 2013).  First instance of onset of strokes is 
reported in persons with SCD as early as six years of age, and affects as many as eight 
percent of individuals under fourteen years old.  Approximately eighty percent of cases 
involving stroke in SCD exhibit complete obstruction of a major cerebral blood vessel, a 
reoccurrence occurs in majority of these cases with three years from the first stroke.  









SCD is therefore a chronic disorder wherein resultant damage to organ systems is 
sustained for the life of the persons suffering from the disease.  The rate and severity of 
damage can vary from an individual to individual and on the occurrence of secondary 
complications associated with SCD.  Spleen damage is observed universally in all SCD 
individuals.  Recurring infarcts result in compromising the already affected spleen 
thereby putting SCD individual at a risk of infections through encapsulated organisms.   
Other chronic manifestations 
 
Approximately more than 50 percent of the population with SCD is affected by 
occurrences of acute chest syndrome.  Acute chest syndrome is presented clinically in 
form of increased body temperature, pain in chest, frequent cough and decreased oxygen 
concentrations overall (M. H. Steinberg 1998).  It is most common but least severe in 
young children, in whom it is often secondary to infection.  In adults, pain often precedes 
this event, and mortality is higher than in children.  Fat embolism resulting from bone 
marrow necrosis is a common cause of the most severe acute chest events (G. R Sergeant 
2013).  Sometimes, fat embolization is accompanied by dramatic falls in the hemoglobin 
and platelet levels, marked leukocytosis, and multi-organ failure.  Recognizing acute 
chest syndrome is critical because aggressive treatment with oxygen, blood transfusions, 
bronchodilators, and antimicrobials can be lifesaving (M. H. Steinberg 1998).   
Osteonecrosis, seen in approximately half of all patients, most often affects the 
heads of the femur and humerus.  In some individuals, it culminates in a severely painful 




Pulmonary hypertension affects approximately one third of adults with sickle cell 
anemia.  Although usually mild, when defined in terms of pulmonary artery systolic 
pressure, its presence portends a poor prognosis as at least a quarter of patients die within 
2 years of its detection (M. H. Steinberg 1998).   
Other severe complications are leg ulcers, nephropathy with renal failure with 
advancing age, and sickle retinopathy, especially in HbSC disease and liver disease.  
Infections are common and major causes of death in children and adults.   
Epidemiology 
 
Based on the estimate by WHO, number of SCD births per year are around 
275,000, one percent of these SCD births are localized to African subcontinent (B. & 
Darlison Modell, M. 2008).  Approximately six million people suffer from SCD in 
Africa, whereas the proportion of SCD individuals is far less in other countries (S. Sheth, 
M. Licursi, and M. Bhatia 2013).   
SCD encompasses a conglomerate of genetic disorders where the pathology stems 
from the bequest of a double heterozygote gene or as homozygously with a gene from 
other parent.  The extent of coming about conditions is subsequently affected by the 
design of discrete hemoglobin qualities, wherein in many populaces, the most widely 
recognized genotype during childbirth is homozygous sickle cell (SS) sickness.   
SCD in populaces of Africa 
 
Although sickle cell trait is abundantly reported through Africa, it is limited to 
one to two percent in north and south of the continent, with majority of the spread of 




al., 2003, based on the DNA structure around the beta gene in HbSS molecule, it has been 
inferred that the sickle gene has predominantly originated at least three indigenous times 
in the human history within Africa.  The areas identified include Central Africa, Senegal 
and Benin (Pagnier J Chebloune Y, Trabuchet G, Faure C, Verdier G, LabieD,Nigon V. 
1988, R. L. Nagel et al. 1985, J. Pagnier et al. 1984).  However, the HbSC sickle gene is 
estimated to be relatively recent mutation reported to be localized primarily to western 
African regions where estimates range from 20 percent in Ghana, two in Nigeria, and 
among the populaces of eastern Africa.  Although sufficient information is available of 
SCD genotype distribution in Africa, information on the incidence of α-thalassemia and 
β-thalassemia is not sufficiently documented.  In a study by Sergeant et al., screening 
approximately hundred thousand births in the cohort of Jamaican individuals observed 
the occurrence of sickle cell trait in almost ten percent of the cases, whereas HbSC was 
observed to occur in around four percent of all cases (G. R. Serjeant et al. 1986), 
compared to individuals with an African origin, the percentages observed were eight and 
two, respectively.  Brazil is the only country in South America where sickle cell genes 
are reported to be seven percent approximately.   
The frequencies of the reported SCD births in Jamaican individuals is one in three 
hundred for sickle cell anemia, one in five hundred for HbSC sickle cell disease, one in 
three thousand beta plus thalassemia and one in seven thousand zero thalassemia (G. R. 






SCD in Populations of India and the Arabian Gulf 
 
Sickle cell trait is widespread in Saudi Arabia, and most prevalent in eastern 
province.  In India, while sickle cell trait is common among the peoples in tribal regions 
in central India (Madhya Pradesh, western Odisha, southeastern Gujarat, and 
Maharashtra) and in the southern part of the country (Kerala and northern Tamil Nadu).  
Based on the depiction of the deoxyribonucleic acid assembly neighboring the beta 
globins, it is observed to differ with an observed presence of HbSS mutation: Asian 
haplotype.  Asian haplotype is observed to be associated with increased concentrations of 
frequent α-thalassemia, and fetal hemoglobin resulting in inhibiting sickling process of 
red blood cells thereby alleviating the associated clinical manifestations of SCD.  
Predominant SCD in Indian and Arabian Gulf is HbSS disease (M. H. Steinberg 1998). 
SCD in United States 
 
 According to Centers of Disease Control and Treatment, 90,000 to 100,000 
individuals suffer from Sickle Cell Disease.  One in five-hundred African-American 
births and one in thirty-six thousand Hispanic births have SCD.  Additionally, SCD in US 
is also prevalent in immigrants from India, Asia Minor, Italy, Greece and immigrants 
from countries bordering Mediterranean and Caribbean seas (Centers of Disease Control 
and Treatment 2012).    
Hassell, 2010 estimated National and state SCD populations based on the 2008 
U.S. Census, using total, African-American, and Hispanic birth-cohort disease prevalence 
derived from the National Newborn Screening Information System.  The study observed 




estimate of 119,100, based on birth-cohort disease prevalence.  The prevalence of SCD 





The replacement of γ-chain synthesis (responsible for development of 60 percent 
to 80 percent of HbF), leads to an increase in the levels of the abnormal HbS levels, 
manifesting as the first symptoms of SCD.  While the rate of transition of γ-chain 
synthesis to β-chain synthesis varies in different individuals, clinically pathological levels 
of HbS are known to be reached within 8th to10th week of birth, leading to development 
of potentially life-threatening complications including pain in hand and leg extremities 
accompanied with swelling, closure of broncho vasculature, primarily triggered due to 
sickle cell crisis, and irregular function of spleen which increases the sufferer’s 
susceptibility to infections (M. H. Steinberg 1998). 
While a study by Stevens et al. 1981 reported 50 percent of the study cohort under 
the age 2 being affected by dactylitis, the first occurrence of dactylitis in children was 
reported to be as early as 10 to 12 week (M. C. Stevens, M. Padwick, and G. R. Serjeant 
1981).  In comparison with the onset of dactylitis, acute splenic sequestration is reported 
to occur in children as young as three months and further six months of age in the first 
year.  While almost sixty-six percent of splenic sequestration cases are reported to present 







 Early years of persons with SCD are marked with occurrence of acute chest 
syndrome, stroke, hypersplenism, and aplastic crises.  While acute chest syndrome results 
in most deaths, Stroke is reported to occur in early years of childhood as well, 
particularly in children with an age of six years, and few instances occurring during the 
age of two years, with an increase in incidence of eight percent by age of fourteen (B. 
Balkaran et al. 1992). 
Later Childhood and Early Adolescence 
 
 With an increase in age, there is a rice in occurrence of pain crisis associated with 
bone, necrosis of avascular type localized to femoral head, leg ulcerations and priapism 
(G. R. Serjeant et al. 1986).  While crisis of bone is common in children, adults suffer 
from dactylitis.  Incidence of bone crises increases with increase in age, particularly in 
males, more than females (K. F. Baum et al. 1987, O. S. Platt et al. 1991).  However the 
frequency of pain crisis and related severity decreases post 25 to 30 years of age.  Factors 
believed to trigger crisis include low fetal hemoglobin levels, infections during third 
trimester of pregnancies, and lower temperatures.  Although bone crisis is the cause of  
approximately 90 percent of hospital admissions in the United States (Y. M. Yang et al. 
1995) and the United Kingdom (M. Brozovic, S. C. Davies, and A. I. Brownell 1987), the 
condition seldom leads to death. 
 While chronic leg ulcers is a commonly observed concern in adolescence, 




fifty percent of Jamaicans and (V. Cumming et al. 2008), five to ten percent of 
Americans are affected (M. Koshy et al. 1989).   
Priapism, affects more than 40 percent of post pubertal males in Jamaica (A. M. 
Emond et al. 1980).  There are two clinical forms of priapism, stuttering priapism, that 
last 2 to 4 hours and major attacks that last 12 hours and are usually trailed by permanent 
vascular damage and impotence.   
Later Adult Life 
 
 Onset of stroke reoccurs around 25 years of age.  Unlike the occurrence of stroke 
in the early years, stroke in later adult life is primarily a result of hemorrhagic and 
subarachnoid hemorrhage (O.S. Platt et al. 1991). 
With later adult life, pulmonary and cardiac complications occur.  Acute chest 
syndrome in later adult life is reported to result in pulmonary hypertension, and therefore 
multiplying the stress on regular cardiac rhythm.  Pulmonary hypertension coupled with 
weakening blood vessels and declining levels of hemoglobin, further promote the 
occurrence of a congestive heart failure (O.S. Platt et al. 1991) 
Furthermore, SCD affected vasculature results in deteriorating renal function past 
the forty years of age, dynamic glomerular fibrosis connected with reducing glomerular 
filtration rates, declining levels of erythropoietin, coupled with slow decrease altogether 
hemoglobin (J. Morris et al. 1991).  Regularly clinically quiet, patients don't give the 
renal variations from the norm yet the step by step diminishing hemoglobin level impedes 






Mortality rates due to SCD are on a decline because of medical advancements 
specifically in early diagnosis of the disease, and presence of more effective 
interventions.  A prior study by Thomas et al. 1982 attributed acute splenic 
sequestrations, acute chest syndrome, and septicemia to be leading cause of deaths in 
second 6 months after the birth of a child.  At later stages although acute chest syndrome 
proves fatal, mortality due to septicemia decrease with active intervention of medications 
to treat septicemia.  After the age of 30 year, however, combined organ harm weakens 
work particularly in the lungs and kidneys prompting death in SCD individuals (Thomas 
et al. 1982).  
 Platt et al. 1994 suggests that genotype of the disease affects the course of disease 
(O. S. Platt et al. 1994).  Patients with HbSC disease and HbSβ+ thalassemia experience 
relatively infrequent episodes of Vaso-occlusive crisis as compared to individuals with 
sickle cell anemia or HbSβ-zero thalassemia.  While presence of HbSS gene can result in 
reduction of average life expectancy by twenty years approximately, people with HbSC 
genotype tend to survive up to 70 to 80 years of their lives.  Platt et al. 1994 reports 
causes of mortality to include presence of an acute pain episode, multiple organ failure, 
cerebral stroke, septicemia, heart failure or contraption of broncho vasculature.   
Pathophysiology of SCD 
 
While the principal pathophysiological features of SCD can be grouped as Vaso 
occlusive/blood viscosity related and hemolysis/vasculopathy related; SCD involves 




regulation, impaired nitric oxide bioavailability, reperfusion injury and inflammation, 
altered hemostasis, defects of intercellular interactions, endothelial cell damage, 
leukocyte and platelet activation, and in all probability, other perturbations of normal 
physiology. (Steinberg 2009)   
The pathophysiology of severe side effects produced by SCD due to the result of 
abnormal hemoglobin are complex (S. K. Ballas 1997, Anonymous 1995, H. F. Bunn 
1997).  “Sticky” red blood cells containing sickled hemoglobin stick to the post-capillary 
vein and narrow the lumen.  Narrowed lumen reduced the speed of flow of blood.  
Consequently, sickled hemoglobin due to blood replacing carried oxygen in tissue 
surrounding the narrowed lumen.  Therefore under deoxygenated conditions, cells with 
HbS form rope like, rigid structure to red blood cells thereby distorting their shape to 
form sickled shape red blood cells.  Irreversibly sickled cells obstruct smaller blood 
vessels resulting in ischemia leading to killing of neighboring cells and thereby initiating 
an inflammatory response leading to sensation of pain.   
Diagnosis of SCD 
 
SCD was reported first identified by James Herrick in 1910.  On following the 
patient for a term of six years, James Herrick came to associate the chronic nature of the 
condition created by irregularly shaped red blood cells to frequent infections, intermittent 
pain in limbs, leg ulcers, and evidence of kidney damage.  James Herrick observed that 
the disease could not be explained by a lesion of any one organ and attributed 
physiological changes in the individual to some unrecognized pathology in the red blood 




No definitive tests of Sickle Cell Disease were available until 1949 when Linus 
Pauling analyzed hemolysate by moving boundary electrophoresis and observed 
difference in mobility of hemoglobin in person with SCD as compared to a person 
without SCD.  (L. Pauling, H. A. Itano, and et al. 1949).  Whereas Vernon Ingram was 
the first scientist to demonstrate that it was the “single amino acid substitution of 
glutamic acid with valine in number six position of beta-globin chain,” by peptide 
analysis that resulted in creating sickle cell hemoglobin.  (V. M. Ingram 1957).  
SCD can be identified by characteristic clinical manifestations of the disease, 
evidence of hemolytic anemia, abnormal morphological findings of red blood cells, or 
positive screening tests of populations or family.   
Sickle cell disease is a constellation of similar but not identical disorders, all of 
which have at least 50 percent HbS in the blood.  The variations of SCD is caused by 
several common and some less common genotypes; homozygotes for the HbS gene are 
said to have sickle cell anemia; common compound heterozygous forms of disease 
include HbSC disease and HbS-β thalassemia.  The cornerstone of the clinical laboratory 
diagnosis is the detection and quantification of HbS. Depending on the context of the 
diagnostic situation, direct detection of the HbS and other globin gene mutations can be 
warranted.  Sickle cell trait is clinically benign and not considered a form of sickle cell 
disease.  
Slide Sickling Test 
 
 Slide sickling test is a test for observing the sickling phenomenon by simply 




included taking the sample of blood to be tested and mixing it with freshly prepared 
solution of a reducing agent, 2 percent sodium metabisulphite and then sealing it under a 
glass coverslip.  Sickling is observed within a few minutes in cells of individuals with 
SCD containing greater than 50 percent HbS (Steinberg 2009).   
Solubility Test 
 
Solubility of deoxygenated hemoglobin S is markedly decreased in comparison to 
a healthy red blood cell.  A visual turbidity is produced due to refraction and deflection of 
light rays by tactoids, a precipitating and insoluble polymer formed when blood with 
deoxygenated hemoglobin S is exposed to reducing substance and concentrated salt 
solutions.  Positive sickling tests should be substantiated by hemoglobin electrophoresis 
or other diagnostic laboratory tests since other sickling hemoglobins also result in a 
positive test.  Therefore the solubility tests can only confirm the presence of sickling 
hemoglobin but it is not specific to HbS (Steinberg 2009).   
 
Treatment of SCD 
 
Primary objective in caring for persons with SCD is to alleviate pain, prohibit 
occurrence of infections, and mitigate secondary conditions.  Children as well as adults 
are often prescribed penicillin in order to prevent infections.  In order to mitigate SCD 
related pain, pain relief medications given to individuals include nonprescription non-
steroidal anti-inflammatory drugs (NSAIDs) or opioids. 
More recently, hydroxyurea is being prescribed for patients with SCD to help 




development of fetal hemoglobin.  Higher concentrations of fetal hemoglobin are 
reported to inhibit sickle cell adhesion on blood vasculature thereby preventing the 
occurrence of sickling events.  
Hydroxyurea is however limited to use in adults only given reported severe 
complication in children under 18 years of age (Ballas et al. 2005).  Other alternative 
treatments include blood transfusion and bone marrow or stem cell transplantation.     
Disease Burden 
 
Although there is an improvement in early diagnosis of SCD, the disease still 
results in significant health care resource utilization overall (Teresa L. Kauf et al. 2009).  
The cost associated with SCD is higher (S. Lanzkron et al. 2006, Miller JL. Steiner CA 
2004, A. S. Wayne, S. E. Schoenike, and C. H. Pegelow 2000) compared to Human 
Immune-deficiency Virus, asthma and epilepsy (K. B. Weiss, S. D. Sullivan, and C. S. 
Lyttle 2000, P. H. van Baal et al. 2008, B. R. Schackman et al. 2006, C. E. Begley et al. 
2000).   
The most cited reason for increase in overall healthcare utilization, specifically, 
increased number of hospitalizations, re-hospitalizations and or ED visits, in patients 
suffering from SCD, is attributed to Vaso Occlusive Crisis (P. J. Nietert et al. 1999, I. P. 
Aisiku et al. 2009, K. A. Anie et al. 2002, M. B. Fosdal and A. W. Wojner-Alexandrov 
2007, K. Frush, R. E. Ware, and T. R. Kinney 1995, W. R. Smith et al. 2008, N. Kunkel 
et al. 1994).  Vaso Occlusive Crises are the hallmark of SCD (CD Reid, Charache, S, 
Lubin, Bh et. al 1995),  and responsible for a large part of morbidity and mortality in 
affected children, adolescents and adults.(S. Charache and D. L. Page 1967, V. N. 




Medical Resource Utilization 
 
Prevention, mitigation or avoidance of a disease condition or related 
complications can result in potential savings that otherwise would have resulted in 
associated economic burden due to the disease condition or related complications.  An 
estimate of potential savings can be achieved by conducting studies that estimate medical 
resource utilization associated with a disease and related complications, thereby, 
providing a valuable insight regarding burden of the disease (E. Akobundu et al. 2006, D. 
P. Rice 2000, J. Lipscomb, P. G. Barnett, et al. 2009). 
All-Cause or Sum of all Costs Approach 
 
The all-cause approach estimates total utilization of persons diagnosed with the 
disease.  When estimating all-cause utilization among persons diagnosed with the 
disease, all patients with a diagnosis of the disease are identified and all health care 
utilization are added up, irrespective of the disease under consideration (E. Akobundu et 
al. 2006). This method is favored for its simplicity.  However this method has been 
reported to overestimate the utilization of diseases which are associated with many 
comorbidities (J. L. Cummings et al. 2002).  Akobundu et al. state that the all-cause 
method is better suited for making cross-country comparisons regarding burden of illness 








The incremental approach estimates the burden directly associated with the 
disease in particular.  There are two methods of calculating incremental estimates: the 
matching method and the regression method.  In the matching method persons with the 
disease are identified and matched with a cohort of persons without the disease.  Persons 
with the disease are matched with those without the disease on specific demographic 
characteristics including age, gender, and race (S. E. Gabriel et al. 2002, S. Balu and J. 
Thomas, 3rd 2006, H. G. Birnbaum et al. 2004).  Incremental burden of the disease is 
calculated by subtracting health care resource utilization of persons without the disease 
from corresponding resource utilization of persons with the disease.  The matching 
method is based on the premise that the matching process accounts for all differences 
between the cohort with the disease and the one without, such that the only remaining 
difference between them is the presence of the disease (E. Akobundu et al. 2006).  
Akobundu et al. highlight that the matched control method is a simple technique of 
estimating utilization of illness but identification of all relevant comorbid conditions as 
well as potential demographic variables is essential for obtaining accurate estimates (E. 
Akobundu et al. 2006).  The regression method has been used by researchers to estimates 
excess utilization of treating a particular disease (S. Balu and J. Thomas, 3rd 2006, B. C. 
Martin et al. 2000, P. Lozano et al. 1997, S. E. Gabriel et al. 2002, H. G. Birnbaum et al. 
2004).  In this method, a regression equation a adjusting for comorbidities and other 
relevant variables is used to estimate incremental utilization associated with a disease (D. 




1997).  Total utilization for patients with the disease are compared to total utilization 
among patients without the disease, and the difference is the estimated regression 
parameter from an equation such as: 
Cost = β0 + β1 Disease + β2 Demographic1 + β3 Demographic2 + β4 Comorbidity1 + β5 
Comorbidity2 + ε  
Where, “Disease” is a binary variable with a value of ‘1’ for persons with the disease and 
‘0’ for persons without the disease, ‘Demographic1’ and ‘Demographc2’ representing 
relevant demographic characteristics that must be adjusted for, ‘Comorbidity1’ and 
‘Comorbidity2’ representing two comorbid conditions and ‘ε’ is the error term.  The 
incremental utilization of the disease is given by the estimate of the parameter β1.  
Controlling for comorbidities has been highlighted as a critical step of the regression 
method, and insufficient rigor can introduce misspecification bias into the regression 
parameter estimate (E. Akobundu et al. 2006, D. W. Lee, J. W. Meyer, and J. Clouse 
2001).  Lee et al. conclude that failing to adjust for sufficient comorbid conditions for 
may result in overestimation of utilization or adjusting for all comorbidities may 
underestimate utilization of illness (D. W. Lee, J. W. Meyer, and J. Clouse 2001).  
Akobundu et al. conclude that the regression method is the preferred method of 
utilization estimation for diseases which are not associated with unobservable factors 





While, several studies have evaluated the trends of health care resource utilization 
due to SCD in children, incremental health care resource utilization due to SCD has not 
been estimated.  Understanding incremental health care resource utilization associated 
with SCD would provide an estimate of burden associated with the disease.  The findings 
should provide valuable data on the societal impact of the disease.  Understanding 
incremental health care resource utilization associated with SCD would provide an 
important estimate of burden associated with the disease.  The findings should provide 
valuable data on the societal impact of the disease.  Understanding the burden of SCD 
can aid in the assessment of the value of new SCD treatments and treatment strategies  
(D. H. Taylor, Jr. and F. A. Sloan 2000, E. A. Finkelstein, I. C. Fiebelkorn, and G. Wang 
2003, R. Z. Goetzel et al. 2004). 
Objectives 
1. The study determined prevalence of SCD in Medicaid beneficiaries in the United 
States using data MarketScan Multi-state Medicaid database.  The study determined 
demographic and clinical characteristics of patients with SCD.  To enhance 
understanding of health care resource utilization in SCD, all-cause health care utilization 
was characterized among persons with SCD, and incremental health care resource 
utilization associated with SCD was determined.   
2. The specific study objectives were to:  




4. 2. Determine all-cause health care resource utilization among persons with SCD, 
5. 3. Determine incremental health care resource utilization associated with SCD by 
categories including hospitalizations, hospital days, emergency room encounters, 
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An analysis was conducted using information from a multi-state Medicaid 
database.  Individuals with Sickle Cell Disease were identified using International 
Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) codes.  One 
year prevalence of SCD was calculated as a ratio of persons with the SCD over the total 
population of covered individuals during the study period from January 1, 2012 through 
December 31, 2012.  Claims data was used to calculate annual all-cause health care 
resource utilization for categories including hospitalizations, hospital days, emergency 
room visits and outpatient visits.  A retrospective cohort design was used to match 
individuals having SCD with individuals without SCD based on age, gender, and race, for 
analysis of incremental health care resource utilization associated with SCD.    
Data Source 
Health insurance claims data from MarketScan multi-state Medicaid claims 






Medicaid is a state-federal health care program for low-income children and 
families, senior citizens, and people with severe disabilities (Center of Medicare and 
Medicaid Services, 2012).  Coverage of Medicaid is provisional to approximately thirty-
one million kids, including fifty-percent of children in United States born to lower than 
established income qualifying levels. Medicaid program also provides for eleven million 
parents who are non-elderly and are classified under the basic income level established 
for Medicaid qualification.  Other eligible enrollees include non-disabled adults, and 
pregnant women (Center of Medicare and Medicaid Services, 2012).  Services covered 
by Medicaid include those mandated by federal laws As of December 31, 2012, there 
were 49,435,610 enrollees in the Medicaid program nationally. (Center of Medicare and 
Medicaid Services, 2012). 
Data files 
 
The Medicaid enrollment data file contains multiple records for each person.  A 
record is generated for an individual each month that the individual qualifies for 
Medicaid services.  The administrative claims database has multiple records containing 
information on each claim for reimbursement of service provided to each Medicaid 
beneficiary.  Information contained in each record includes demographic and eligibility 
related data.  Demographic data include age, gender, race, enrollment period, and status 
on Medicare coverage.     
Details recorded for each service vary by type of service.  For inpatient services, 




related grouping, principal procedure, procedure code and up to ten procedure modifiers, 
revenue code, admit date, discharge date, dates of first and last service, discharge status, 
and, length of hospital stay.   
For outpatient services, physician services, and dental services, details on primary 
diagnosis and up to three additional diagnoses, principal procedure, procedure code and 
up to four procedure modifiers, admit date, discharge date, provider identifier, provider 
and provider type are recorded.  The diagnoses are reported using the International 
Classification of Diseases, 9th revision, Clinical modification (ICD-9 CM) system 
Ethical Considerations 
Institutional Review Board approval for the study was obtained from the 
Committee on the Use of Human Subjects in Research at Purdue University, West 
Lafayette, Indiana. 
Study Sample 
Analytic samples were drawn based on each study objective.  The inclusion 
criteria and exclusion criteria for each analytic sample are described below. 
Prevalence of SCD Sample 
 
To be eligible for inclusion in the sample for determination of SCD prevalence, an 
individual was required to be continuously enrolled in a tracked health plan during the 
study period from January 1, 2012 through December 31, 2012. 
 
 







To be eligible for inclusion in the sample for determining all-cause and 
Incremental healthcare utilization, individuals were required to be enrolled in a tracked 
health plan for twelve months in the period from January 1, 2012 through December 31, 
2012,  and were required to have an ICD-9-CM diagnosis code for sickle-cell thalassemia 
without crisis (282.41), or, sickle-cell thalassemia with crisis (282.42), or,  Sickle-cell 
disease, unspecified (282.60), or, HbSS disease without crisis (282.61), or,  HbSS disease 
with crisis (282.62), or,  Sickle-cell/HbC disease without crisis (282.63), or, Sickle-
cell/HbC disease with crisis (282.64), or, other sickle-cell disease without crisis (282.68), 
or, other sickle-cell disease with crisis (282.69).  Persons with ICD-9-CM code for sickle-
cell trait (282.5) were excluded from the analytic sample. 
Comparison Cohort 
The SCD Cohort was matched on age, gender, and race, with a sample of 
individuals without SCD.  To be included in the non-SCD cohort for analysis of 
incremental health care resource utilization, an individual was required to be enrolled in a 
tracked health plan for twelve months from January 1, 2012 through December 31, 2012. 
Study Variables 
All-Cause and Incremental Health Care Resource Utilization 
 
All-cause health care resource utilization among persons with SCD was estimated 
from patients’ insurance claims during the period from January 1, 2012 through 
December 31, 2012, for number of hospitalizations, hospital days, emergency room 




identifying and counting the number of unique visits per patient.  Claims for outpatient 
facilities or emergency rooms were identified by the place of service and provider 
category associated with the claim.  One visit at an outpatient facility or an emergency 
room was defined as a summation of all visits to that facility per day.  For example, if a 
patient visited his primary physician’s office three times in one day and on the same day, 
visited a particular laboratory twice, the resultant visit count for that day was one.  The 
total number of visits per patient for emergency rooms and outpatient facilities were 
counted and reported. 
Demographic Variables 
 
Demographic information for individuals in the study sample was gathered from 
enrollment data files.  Details were available on birth year, gender, race, and Medicare 
coverage status per individual enrolled in the study period.  The birth year of each 
enrolled individual was subtracted from 2012 to obtain age of enrollees during the study 
period.  Race was categorized Blacks or others.  Medicare coverage status was coded 
dichotomously based on whether the enrollee had Medicare coverage in addition to 
Medicaid coverage.  
For bivariate and multivariate analyses, age was treated as a continuous variable.  
Gender was recoded such that a value of ‘1’ indicated male and ‘0’ indicated female.  
Race categories were collapsed into two groups-blacks and non-blacks.  Non-blacks were 







For each claim, an enrollee had an admit date that corresponded to inpatient 
service, a value of ‘1’ was assigned to indicating one hospitalization.  If the category of 
service variable in the claims database did not correspond to inpatient service then a 
value of ‘0’ was assigned to the hospitalization variable.  All inpatient service claims 
with the same admit dates were considered as one hospitalization.  Mean hospitalizations 
per enrollee during the study period. 
Hospital Days 
 
For each claim, if the enrollee in the claims database with a hospitalization, 
discharge date was subtracted from the admit date in order to calculate the length of per 
hospital stay for the enrollee.  If the individual did not have a hospitalization, value of ‘0’ 
was assigned to the hospital days variable.  For each enrollee all such hospital days were 




Outpatient visits were identified based on provider type and place of service 
categories.  For each claim, if the enrollee in the claims database had a visit to an 
outpatient place of service or to an outpatient provider, a value of ‘1’ was assigned to 
enrollee indicating one outpatient visit.  If the category of service variable in the claims 
database did not correspond to an outpatient place of service or an outpatient provider 




claims with the same admit dates were considered as one outpatient visit.  For each 
enrollee all such outpatient visits were summed and averaged to calculate average 
outpatient visits per enrollee during the study period. 
Emergency Room Visits 
 
Emergency room visits were identified based on provider type and place of 
service categories.  For each claim, if the enrollee in the claims database had a visit to an 
Emergency room place of service or provider type, a value of ‘1’ was assigned to enrollee 
indicating one outpatient visit.  If the category of service variable in the claims database 
did not correspond to an Emergency room place of service or provider type then a value 
of ‘0’ was assigned to the Emergency room visits variable.  All Emergency room visit 
claims with the same admit dates were considered as one Emergency room visit.  For 
each enrollee all such Emergency room visits were summed and averaged to calculate 
average Emergency room visits per enrollee during the study period. 
Charlson Comorbidity Index 
 
The Charlson Comorbidity Index categorizes comorbidities of patients based on 
the International Classification of Diseases (ICD) diagnosis codes found in administrative 
data, such as hospital abstracts data.  A score of zero indicates that no comorbidities were 
found.  The higher the score, the more likely the predicted outcome will result in 
mortality or higher resource use (Greenfield S and Nelson E, 1992).  A Charlson 
comorbidity index score was computed for each individual using an algorithm provided 




individuals in the study was based on their claim records for the entire year of 2012.  The 
score was categorized in three categories, ‘0,’ for individuals with no comorbidities, ‘1’ 
for individuals with 1 comorbidity, and ‘2’ for individuals with 2 or more comorbidities.  
Statistical Analysis 
Data were analyzed using SAS for Unix Version 9.2 and STATA for UNIX 
version 12.  An a priori alpha level of 0.05 was used in all statistical analysis.  Frequency 
distributions were developed and Chi-square tests were used to assess statistical 
distribution between persons with or without SCD on demographic variables and clinical 
variables including age, gender, and, race.  Statistical analyses for each objective are 
explained in the sections below. 
Prevalence of SCD 
 
The number of individuals with ICD-9 diagnosis codes for sickle-cell thalassemia 
without crisis (282.41), or, sickle-cell thalassemia with crisis (282.42), or,  Sickle-cell 
disease, unspecified (282.60), or, Hb-SS disease without crisis (282.61), or,  Hb-SS 
disease with crisis (282.62), or,  Sickle-cell/Hb-C disease without crisis (282.63), or, 
Sickle-cell/Hb-C disease with crisis (282.64), or, other sickle-cell disease without crisis 
(282.68), or, other sickle-cell disease with crisis (282.69), and enrolled continuously 
during the period from January 1, 2012 through December 31, 2012, were identified and 
divided by the total population of covered individuals, during the same study period.  
Ninety-five percent confidence intervals of the estimated prevalence was constructed.   





Annual all-cause health care resource utilization was calculated for, number of 
hospitalizations, hospital days, , emergency room visits, and outpatient visits from 
patients’ insurance claims, during the period from January 1, 2012 through December 31, 
2012.  Unadjusted means and 95 percent confidence intervals were computed for each 
utilization category.  Wilcoxon Mann Whitney tests were used to detect distributions 
between individuals with SCD and those without SCD, for each resource utilization 
variable. 
Incremental Health Care Resource Utilization Associated with SCD 
 
Individuals with SCD were matched one to one based on age, gender, and race 
with a comparison group of individuals without SCD for estimation of incremental 
annual health care resource utilization associated with SCD.  Multivariate regression 
models were developed to estimate incremental health care resource utilization associated 
with SCD adjusting for co-morbidity index.  A systematic approach based on 
examination of data distributional characteristics and assessment of fit of alternative 
models was used to select a multivariate model for analysis.  Residuals of ordinary least 
squares regression models with untransformed and models with log transformed 
utilization variables were examined for violation of assumptions.  P-values lower than 
0.05 for each Kolmogorov-Smirnov test were used to assess whether residuals were 
normally distributed (D'Agostino and Stephens 1986).  Glejser tests were used to 
investigate whether residuals were significantly associated with independent variables 
(Glejser 1969).  Generalized linear models were also developed and tested for model fit.  
Presence of over dispersion of dependent variables was assessed using Vuong tests (Long 




used to determine comparative fit of alternative generalized linear models (Long and 
Freese 2006; Vuong 1989; Cameron and Trivedi 1986)    
Individual regression models were developed to estimate independent association 
between SCD and utilization of health services such that individual models were 
developed for hospitalizations, hospital days, outpatient visits, and for emergency room 
visits.  A binary predictor variable for SCD was included in each model and covariates in 
each model included age, gender, race, co-morbidity index score, and Medicare coverage, 
to adjust for those risk factors.  Auto-correlation was conducted to assess correlation 
between covariates before adding them to the model.  The general regression model 
developed for estimating incremental health care resource utilization is shown below: 
Resource Utilization = β0 + β1 SCD + β2 Age + β3 Gender + β4 Race 
        + β5 Charlson Comorbidity Score + β6  Medicare Coverage  + ε   
where, “Resource Utilization” is the dependent variable for a type of health care resource 
utilization including hospitalizations, hospital days, outpatient visits, and for emergency 
room visits.  “SCD” is a binary variable with a value of ‘1’ for persons with SCD and ‘0’ 
for persons without SCD.  ‘Race’ is a binary variable with a value of ‘1’ for blacks and 
‘0’ for others.  ‘Age’ is a continuous variable that represents the age of the individual.  
“Gender” is a binary variable with a value of ‘1’ for males and ‘2’ for females.  
“Charlson Comorbidity Score” is a continuous variable, while, “Medicare Coverage,” is a 
binary variable with a value of ‘1’ for persons with both Medicare and Medicaid 
coverage and ‘0’ for persons with only Medicaid coverage.  ‘ε’ is the error term and 
incremental resource utilization associated with the disease is the estimate of the 
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Prevalence of SCD 
Figure 1 shows the sample selection procedure and results for selection of the 
sample for determining prevalence of SCD.  There were 5,136,748 persons continuously 
enrolled during the period from January 1, 2012 through December 31, 2012.   
Of those 5,136,748 persons, 8,652 individuals satisfied sample selection criteria 
of having at least one inpatient visit or more than two outpatient visits, were continuously 
enrolled from January 1, 2012 through December 31, 2012 and having an ICD-9-CM 
diagnosis code for sickle-cell thalassemia without crisis (282.41), or, sickle-cell 
thalassemia with crisis (282.42), or,  Sickle-cell disease, unspecified (282.60), or, Hb-SS 
disease without crisis (282.61), or,  Hb-SS disease with crisis (282.62), or,  Sickle-
cell/Hb-C disease without crisis (282.63), or, Sickle-cell/Hb-C disease with crisis 
(282.64), or, other sickle-cell disease without crisis (282.68), or, other sickle-cell disease 
with crisis (282.69).   
The prevalence of SCD was one in 594 persons or 1,684 cases per million 
population, or 168 per thousand individuals.  Ninety-five percent confidence interval was 
estimated to be 1,649 to 1,720 cases per million population. 











Persons continuously enrolled from January 1, 2012 through 
December 31, 2012 
8,652 
 
Satisfying Inclusion criteria of having SCD and one inpatient 
visit or two or more outpatient visits and continuously enrolled 
from January 1, 2010 through December 31, 2012. 
5,128,096 
 





Demographic Characteristics of Prevalence Sample  
 
Table 1 shows characteristics of the prevalence sample and compares it to the 
total population covered by the administrative database.  In the prevalence sample, 52 
percent of individuals with SCD were under 19 years of age.  The proportion of females 
with SCD (55 percent) was higher than males with SCD (45 percent).  Seventy-four 
percent of the study sample was black. 
Sample Characteristics 
 
Figure 2 shows the sample selection procedure and results for selection of the 
sample for determining all-cause resource utilization as well as for determining 
incremental resource utilization.  Out of 5,136,748 persons covered in the database, 8,652 
individuals satisfied sample selection criteria of being continuously enrolled in tracked 
health plan and diagnosed with SCD as well as having at least one inpatient admission or 
greater than two outpatient visits.   
The individuals with a diagnosis for SCD were linked one-to-one with individuals 
without SCD, resulting in 8,652 persons in the comparison group and a total of 17,304 
persons in the sample for determining all-cause resource utilization and determining 




Table 2 shows that 49 percent of the sample was under 18 years old.  Age was 
categorized in increments of 4.  Since persons with SCD were linked one-to-one on age 




observed on age between persons with SCD and those without SCD.  The mean age of 
the sample was 21.86 years with a standard deviation of 17.06 
Gender 
Table 3 shows sample distribution based on gender.  The proportion of females 
with SCD was higher (54.6 percent) than males with SCD (45.3 percent).  Since persons 
with SCD were linked one-to-one on gender with a comparison sample of persons 
without SCD, no significant gender differences were observed between person with SCD 
and those without SCD.  
Race 
 
Table 4 shows the distribution of the sample by race.  Race categories were 
collapsed into two groups-blacks and non-blacks.  Non-blacks were given a value of ‘0’ 
and blacks were assigned a value of ‘1.’ 
The sample was divided into two ethnicities Blacks and others.  The largest 
proportion of the sample was blacks (95.4 percent).  Percentage was based on non-
missing information for race across the study sample. 
Charlson comorbidity Index Score 
 
Table 5 describes the distribution of the study sample and compares persons with 
SCD and those without SCD with respect to Charlson Comorbidity Index scores.   The 
score was categorized in three categories, ‘0,’ for individuals with no comorbidities, ‘1’ 
for individuals with 1 comorbidity, and ‘2’ for individuals with 2 or more comorbidities.  
Sixty-five percent of the sample had a Charlson comorbidity score of zero 




Comorbidity Index.  Approximately, 21 percent of the sample had a score of one and 13 
percent of the sample had a score of two.  
Among individuals with SCD, 52.09 percent had a Charlson comorbidity score of 
zero indicating that they did not have any of the comorbid conditions listed in the 
Charlson Comorbidity Index.   
Significantly higher proportions of comorbidities were observed for individuals in 
the SCD group for each level of Charlson Comorbidity Index score above zero, compared 
to the those individuals without SCD, for a Charlson score of ‘1’ (29.13 percent vs. 13.79 






          Table 1:   Demographic distribution of persons with Sickle Cell Disease, with and without Sickle Cell Crisis and                        
Total covered population. 






Total Covered Population 
(n= 5,136,748) 
Characteristic  Number Percent Number Percent Number Percent  Number Percent 
Age (in years)   
Under 5  1,164 13.4 568 6.5 596 6.8 847,085 16.4
5 to 9  1,327 15.3 759 8.7 568 6.5 964,742 18.7
10 to 14  1,122 12.9 599 6.9 523 6.0 819,669 15.9
15 to 19  1,031 11.9 579 6.6 452 5.2 577,118 11.2
20 to 24  909 10.5 633 7.3 276 3.1 188,478 3.6
25 to 29  674 7.7 477 5.5 197 2.2 181,060 3.5 
30 to 34  584 6.7 408 4.7 176 2.0 168,973 3.2
35 to 39  441 5.1 259 2.9 182 2.1 137,153 2.6
40 to 44  383 4.4 229 2.6 153 1.7 130,592 2.5
45 to 49  300 3.4 162 1.8 138 1.6 140,788 2.7
50 to 54  247 2.8 120 1.3 127 1.4 162,725 3.1
55 to 59  191 2.2 79 0.9 112 1.2 160,389 3.1
60 to 64  117 1.3 35 0.4 82 0.9 132,907 2.5
65 and over  163 1.8 65 0.7 98 1.1 525,069 10.2
    
Gender     
 Female  4,728 54.6 2,641 30.5 2,087 24.1 2,887,507 56.2
  Male  3,924 45.3 2,331 26.9 1,593 18.4 2,249,241 43.8 
    
Race    
Blacks  6,401 73.9 3,628 41.9 2,773 32.0 1,784,839 34.7
Whites  223 2.5 67 0.7 156 0.5 2,355,767 45.8
 Hispanics  81 0.9 36 0.4 45 8.1 371,756 7.2










Figure 2: Sample Selection Results to Determine All-Cause and Incremental Health 
5,136,748 
 
Persons continuously enrolled from January 1, 2012 
through December 31, 2012 
8,652
 
Cases remaining after exclusions 
17,304
 




Persons with no SCD diagnosis or having fewer than 
12 months of enrollment
8,652
 
Persons without SCD linked on age, gender, and race 






Table 2.  Distribution of Study Sample by Age (n=17,304) 
 ______________________________________________________________________  
   Number 
Age  (n=17,304) Percent 
 ______________________________________________________________________  
Age     
  Under 5 2,328 13.4 
  5 to 9 2,654 15.3 
  10 to 14 2,244 12.9 
  15 to 19 2,062 11.9 
  20 to 24 1,818 10.5 
  25 to 29 1,348 7.7 
  30 to 34 1,168 6.7 
  35 to 39 882 5.1 
  40 to 44 766 4.4 
  45 to 49 600 3.4 
  50 to 54 494 2.8 
  55 to 59 382 2.2 
  60 to 64 234 1.3 
  65 and over 326 1.88  
 ______________________________________________________________________  






Table 3.  Distribution of Study Sample by Gender (n=17,304) 
 ______________________________________________________________________  
   Number 
Gender (n=17,304) Percent 
 ______________________________________________________________________  
Female  9,456 54.6 
 
Male  7,848 45.3 





Table 4.  Distribution of Study Sample by Race (n=17,304) 
 ______________________________________________________________________  
   Number 
Race (n=17,304) Percent 
 ______________________________________________________________________  
Blacks  12,802 73.9 
 







Table 5.  Distribution of Total Study Sample and Distribution of Persons with or without SCD by Charlson Comorbidity Index 
 ____________________________________________________________________________________________________________ 
  Total Sample With SCD Without SCD   
  (n=17,304) (n=8,652) (n=8,652) 
  ________________ ________________________ _________________________  
Charlson Number (Percent) Number (Percent) Number (Percent) p-value1  
Comorbidity Index 
 ____________________________________________________________________________________________________________ 
 0 11,308 (65.35) 4,507  (52.09) 6,801  (78.61) <0.001 
 
 1 3,713 (21.46) 2,520  (29.13) 1,193  (13.79) <0.001 
 
 2 2,283 (13.19) 1,625  (18.78) 658    (7.61) <0.001 
 ____________________________________________________________________________________________________________ 





Unadjusted Annual Health Care Resource Utilization 
 
Mean unadjusted annual health care utilization for persons with or without SCD is 
reported in Table 7.  Mean annual unadjusted hospitalizations among individuals with 
SCD were 1.39 (95 percent C.I.: 1.34 to 1.45).  Mean annual unadjusted hospital days 
among individuals with SCD were 7.04 (95 percent C.I.: 6.68 to 7.4).  Mean annual 
unadjusted outpatient visits among individuals with SCD were 24.7 (95 percent C.I.: 
23.92 to 25.59).  Mean annual unadjusted emergency room visits among individuals with 
SCD were 3.71 (95 percent C.I.: 3.52 to 3.90).    
Compared to individuals with SCD, significantly lower mean unadjusted 
hospitalizations, mean unadjusted hospital days, mean unadjusted outpatient visits, and 
mean unadjusted emergency department visits were observed among those without SCD.  
Mean annual unadjusted hospitalizations among individuals without SCD were 0.10 (95 
percent C.I.: 0.09 to 0.11).  Mean annual unadjusted hospital days among individuals 
without SCD were 0.50 (95 percent C.I.: 0.42 to 0.59), outpatient visits were 14.18 (95 
percent C.I.: 13.40 to 14.96), and mean unadjusted emergency department visits among 





Table 6.  Unadjusted Annual Health Care Resource Utilization among Persons with SCD and those without SCD 
 ____________________________________________________________________________________________________________ 
 With SCD  Without SCD  
 (n=8,652) (n = 8,652) 
 _____________________  _____________________  
  Mean Mean 
Health Care Resource Category (95% CI) (95% CI)   p-value 1 
 ____________________________________________________________________________________________________________ 
Hospitalizations 1.39** 0.10   <0.001 
  (1.34 to 1.45) (0.09 to 0.11) 
 
Hospital days 7.04** 0.50   <0.001 
  (6.68 to 7.40) (0.42 to 0.59)  
 
Outpatient visits 24.7** 14.18   <0.001 
  (23.92 to 25.59) (13.40 to 14.96) 
 
Emergency room visits 3.71** 0.89   <0.001 
  (3.52 to 3.90) (0.84 to 0.94) 
 ____________________________________________________________________________________________________________ 
 
** p-value <0.001 




Incremental Annual Health Care Resource Utilization Associated with SCD  
A sequential assessment of potential regression techniques after evaluating the 
data distributional characteristics were examined and sequential assessment of potential 
regression techniques was conducted to select an appropriate model, for analysis of 
incremental resource utilization associated with SCD.  The models were examined in 
sequence beginning with ordinary least squares regression on the untransformed  
dependent variables, followed by ordinary least squares regression on the log transformed 
dependent variables, generalized linear models and zero-inflated generalized linear 
models.  Residuals of ordinary least squares regression models with untransformed and 
models with log transformed utilization variables, showed violation of assumptions of 
normality and constant variance.  P-values lower than 0.05 for each Kolmogorov-
Smirnov test showed that residuals for each ordinary least squares regression model were 
not normally distributed (D'Agostino and Stephens 1986).  Results of each Glejser test 
showed p-values lower than 0.05, confirming that residuals were significantly associated 
with independent variables (Glejser 1969).  Therefore, generalized linear models were 
developed and tested for model fit.  Medical resource utilization variables in this study 
had a high number of observations with zeros.  Over-dispersion of each resource 
utilization variable evidenced by p-values less than 0.05 for Vuong tests, suggested a 
need for a zero-inflated generalized linear model (Long and Freese 2006; Vuong 1989).  
Significant likelihood ratio tests, shown by p-values less than 0.05 indicated that for each 




inflated Poisson models or negative binomial regression models (Long and Freese 2006; 
Vuong 1989; Cameron and Trivedi 1986).    
Table 8 shows the incremental hospitalizations in persons with SCD as compared 
to persons without SCD, after controlling for covariates such as age, gender, and race, 
comorbidities, and Medicare coverage status of the analytical sample.  Persons with SCD 
were estimated to have 1.39 more hospitalizations, or 139 more hospitalizations per 100 
persons as compared to persons without SCD.   
Table 9 shows the incremental hospital days in persons with SCD as compared to 
persons without SCD, after controlling for covariates such as age, gender, and race, 
comorbidities, and Medicare coverage status of the analytical sample.  Persons with SCD 
were estimated to have 6.94 more hospital days or 694 more hospital days per 100 
persons as compared to persons without SCD.   
Table 10 shows the incremental Outpatient visits in persons with SCD as 
compared to persons without SCD, after controlling for covariates such as age, gender, 
and race, comorbidities, and Medicare coverage status of the analytical sample.  Persons 
with SCD were estimated to have 7.27 more outpatient visits, or 727 more outpatient 
visits per 100 persons as compared to persons without SCD.   
Table 11 shows the incremental Emergency room visits in persons with SCD as 
compared to persons without SCD, after controlling for covariates such as age, gender, 
and race, comorbidities, and Medicare coverage status of the analytical sample.  Persons 
with SCD were estimated to have 2.66 more emergency room visits, or 266 more 




Table 7.  Annual Incremental Hospitalizations Associated with SCD (n=17,304) 
 
Variable Average marginal effect Standard error p-value 1,2 
Sickle Cell Disease    
No-Sickle Cell Disease Reference   
Yes-Sickle Cell Disease 1.38 0.05 <0.001 
    
Age3 0.001 0.0009 <0.05 
    
Gender    
Male Reference   
Female 
 
0.02 0.02 0.233 
Race    
Non-Blacks Reference   
 Blacks 0.11 0.02 <0.001 
    
Medicare    
No-Medicare Coverage Reference   
Yes-Medicare Coverage 0.28 0.03 <0.001 
    
Charlson Comorbidity Score4 0.48 0.02 <0.001 
 
1 Zero-inflated negative binomial regression 
2 p-value less than 0.05 was considered significant 
3 Age was a continuous variable in the model 




Table 8.  Annual Incremental Hospital Days Associated with SCD (n=17,304) 
 
Variable Average marginal effect Standard error p-value 1,2 
Sickle Cell Disease    
No-Sickle Cell Disease Reference   
Yes-Sickle Cell Disease 6.94 0.29 <0.001 
    
Age 3 0.06 0.007 <0.001 
    
Gender    
Male Reference   
Female 
 
0.42 0.15 <0.05 
Race    
Non-Blacks Reference   
 Blacks 0.55 0.17 <0.05 
    
Medicare    
No-Medicare Coverage Reference   
Yes-Medicare Coverage 0.91 0.21 <0.001 
    
Charlson Comorbidity Score 4 2.7 0.12 <0.001 
 
1 Zero-inflated negative binomial regression 
2 p-value less than 0.05 was considered significant 
3 Age was a continuous variable in the model 





Table 9.  Annual Incremental Outpatient Visits Associated with SCD (n=17,304) 
 
 
1 Zero-inflated negative binomial regression 
2 p-value less than 0.05 was considered significant 
3 Age was a continuous variable in the model 
4 Charlson Comorbidity Index was a continuous variable in the model 
  
Variable Average marginal effect Standard error p-value 1,2 
Sickle Cell Disease    
No-Sickle Cell Disease Reference   
Yes-Sickle Cell Disease 7.27 0.37 <0.001 
    
Age 3 0.18 0.01 <0.001 
    
Gender    
Male Reference   
Female 
 
3.26 0.35 <0.001 
Race    
Non-Blacks Reference   
 Blacks 0.67 0.39 <0.05 
    
Medicare    
No-Medicare Coverage Reference   
Yes-Medicare Coverage 7.00 0.57 <0.001 
    




Table 10.  Annual Incremental Emergency Room Visits Associated with SCD (n=17,304) 
 
1 Zero-inflated negative binomial regression 
2 p-value less than 0.05 was considered significant 
3 Age was a continuous variable in the model 
4 Charlson Comorbidity Index was a continuous variable in the model 
  
Variable Average marginal effect Standard error p-value 1,2 
Sickle Cell Disease    
No-Sickle Cell Disease Reference   
Yes-Sickle Cell Disease 2.66 0.08 <0.001 
    
Age 3 0.02 0.002 <0.05 
    
Gender    
Male Reference   
Female 
 
0.22 0.06 <0.001 
Race    
Non-Blacks Reference   
 Blacks 0.37 0.07 <0.001 
    
Medicare    
No-Medicare Coverage Reference   
Yes-Medicare Coverage 0.15 0.09 0.076 
    




Sub-Group Analysis by whether Diagnosed with Sickle Cell Crisis 
Unadjusted Annual Health Care Resource Utilization by whether Diagnosed with                        
Sickle Cell Crisis 
 
Unadjusted resource utilization among persons with SCD by whether diagnosed 
with sickle cell crisis or not is reported in Table 12.   
Mean annual unadjusted hospitalizations were more than seven times higher 
among SCD patients with sickle cell crisis 2.17 (95 percent C.I.: 2.08 to 2.25) as 
compared to SCD patients without sickle cell crisis 0.34 (95 percent C.I.: 0.31 to 0.38).  
Individuals with SCD and sickle cell crisis had more than six times greater mean annual 
unadjusted hospital days 10.98 (95 percent C.I.: 10.41 to 11.54) as compared to SCD 
patients without sickle cell crisis 1.72 (95 percent C.I.: 1.47 to 1.98).  Mean annual 
unadjusted outpatient visits were higher among individuals with sickle cell crisis 26.12 
(95 percent C.I.: 25.14 to 27.10) as compared to those without sickle cell crisis 22.91 (95 
percent C.I.: 21.46 to 24.35).  Mean annual unadjusted emergency room visits were 
approximately 4 times as high among individuals with crisis 5.28 (95 percent C.I.: 4.97 to 








Table 11.  Unadjusted Annual Health Care Resource Utilization among Persons with Crisis a and those without Crisis 
 ____________________________________________________________________________________________________________ 
 
 With Crisis Without Crisis  
 (n=4,972) (n = 3,680) 
 _____________________  ____________________ 
 
 Mean Mean 
Health Care Resource Category (95% CI) (95% CI)    p-value 1 
 ____________________________________________________________________________________________________________ 
 
Hospitalizations 2.17** 0.34     <0.001 
  (2.08 to 2.25) (0.31 to 0.38) 
 
Hospital days 10.98** 1.72     <0.001 
  (10.41 to 11.54) (1.47 to 1.98)  
 
Outpatient visits 26.12** 22.91     <0.001  
  (25.14 to 27.10) (21.46 to 24.35) 
 
Emergency room visits 5.28** 1.58     <0.001 
  (4.97 to 5.60) (1.45 to 1.72) 
 ____________________________________________________________________________________________________________ 
 
** p-value <0.001 
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Sickle Cell Disease (SCD) is a group of genetic disorders that is characterized by 
presence of abnormal haemoglobin, specifically the protein, haemoglobin S, in red blood 
cells.  According to the Centers for Disease Control and Prevention (CDC), it is estimated 
that one out of every 500 African-American births and one out of every 36,000 Hispanic-
American births has SCD (M. H. Steinberg 1999).  Mvundara et al. 2009 assessing 
prevalence in a children under 17 years old covered by Medicaid, reports one in 847 
persons to have SCD.  SCD also occurs in descendants of immigrants from Greece, Italy, 
India, Asia Minor and countries bordering the Mediterranean and Caribbean Seas.   
The irregular haemoglobin in persons with SCD causes red blood cells to 
become rigid and sickle-shaped with reduced oxygen carrying capacity thereby 
manifesting an onslaught of clinical complications (Steinberg 2009).  Abnormal red 
blood cells increase the viscosity of blood, resulting in occlusion of blood vessels, 
leading to occurrence of frequent fatigue, headaches and chronic anaemia.  Over time, 
with increase in age, and frequent onset of acute painful episodes of Sickle Cell Crisis, 
irreversible damage to muscle, blood vessels, and internal organs occur, leading to 
chronic lung disease, pulmonary hypertension, and susceptibility to infections, avascular 




complications of SCD such as acute chest syndrome, asthma and stroke can potentially 
be life threatening, often resulting in early age mortality or leading to significant health 
care resource utilization in terms of frequent re-hospitalizations, physician visits and 
emergency room visits (O. S. Platt et al. 1991).  Average life expectancy of a person 
with SCD is 42 to 48 years of age (M. H. Steinberg 1999).    
This study provides a current description of the epidemiology of SCD by 
estimating its one year prevalence, all-cause health care resource utilization, incremental 
health care resource utilization and analyses health care resource utilization in persons 
with sickle cell crisis.  (D. D. Amendah et al. 2010, M. A. Blinder et al. 2013, Teresa L. Kauf et al. 2009, D. C. Brousseau et al. 2010, A. K. Dickerson et al. 2012, J. L. Raphael et al. 2013, W. C. Wang et al. 2013) (D. D. Amendah et al. 2010).    
Overall, assessment of health care resource utilization will aid in providing a 
general estimate of the burden of SCD, it will also allow comparison of resource use 
categories amongst each other in order to provide an insight to health care payers, and 
decision makers to further investigate reasons for respective utilizations.  
Objectives 
The specific objectives for this study were to  
1. determine prevalence of SCD, 
2. determine all-cause health care resource utilization among persons with SCD,  
3. determine incremental health care resource utilization associated with SCD by 





4. determine all-cause health care resource utilization among persons with Sickle 
Cell Crisis by categories including hospitalizations, hospital days, emergency 
room visits and  outpatient visits 
Methods 
An analysis was conducted using information from a multi-state Medicaid 
database.  Individuals 0 to >65 years old with Sickle Cell Disease were identified using 
International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) 
codes.  One year prevalence of SCD was calculated as a ratio of persons with the SCD 
over the total population of covered individuals 0 to >65 years old during the one year 
period from January 1, 2012 through December 31, 2012.  Claims data was used to 
calculate annual all-cause health care resource utilization for categories including 
hospitalizations, hospital days, emergency room visits and outpatient visits.  A 
retrospective cohort design was used to match individuals having SCD with individuals 
without SCD based on age, gender, and race, for analysis of incremental health care 
resource utilization associated with SCD.  
Ethical Consideration 
 
Institutional Review Board approval for the study was obtained from the 







Prevalence of SCD 
 
To be eligible for inclusion in the sample for determination of prevalence of SCD, 
an individual was required to be continuously enrolled in a tracked health plan anytime 
during the period from January 1, 2012 through December 31, 2012. 
Analysis 
 
Data were analyzed using SAS for Unix Version 9.2 and STATA for UNIX 
version 12.  Frequency distributions were developed to describe the sample with SCD 
and those without SCD on, demographic variables.  To estimate one-year prevalence of 
SCD, the number of individuals with ICD-9 diagnosis codes for “Sickle Cell Disease” 
and enrolled continuously during the period from January 1, 2012 through December 31, 
2012, were identified and divided by the total population of covered individuals during 
the same one year period.  Health care resource utilization by specific categories was 
calculated for each individual.  Unadjusted means and 95 percent confidence intervals for 
utilization in each category were also computed, and Wilcoxon Mann Whitney tests were 
used to detect differences between the groups.   
Individual regression models were developed to estimate independent association 
between SCD and utilization of health services such that individual models were 
developed for hospitalizations, hospital days, outpatient visits, and emergency room 
visits.  A binary predictor variable for SCD was included in each model and covariates in 
each model included age, gender, co-morbidity index score, race, and Medicare coverage, 
to adjust for these risk factors.  Sub-group analysis examined resource utilization 




Results and Discussion 
Demographic Characteristics of Prevalence Sample  
In the prevalence sample, 53.5 percent of individuals with SCD were 19 years of 
age and younger.  The proportion of females with SCD (55 percent) was higher than for 
males with SCD (45 percent).     
Prevalence of SCD 
 
From 5,136,748 persons enrolled during the period from January 1, 2012 through 
December 31, 2012, there were 8,652 individuals having an ICD-9-CM diagnosis code 
for “Sickle Cell Disease.”  The number of SCD patients (8,652) was divided by the 
number of all covered individuals (5,136,748) to calculate the one-year prevalence of the 
disease.  The prevalence of SCD was one in 594 persons or 1.68 cases per thousand 
population.  The only prior available estimate of prevalence of SCD in Medicaid 
population is reported by Mvundara et al. 2009.  According to Mvundara, prevalence of 
SCD was one in 847 persons or 1.18 cases per thousand.  However, the study sample 
only included children below 17 years of age.  However, there is an increase in average 
life-expectancy of individuals with SCD, attributed to improved standards of care, early 
diagnosis, and screening of birth disorders, and availability of drug therapies like 
Hydroxyurea to mitigate the complications of SCD.  Therefore, it is necessary to expand 
the inclusion criteria to include adults as well as children in order to more accurately 
estimate the prevalence of SCD in Medicaid populations in US. 
Hassell, 2010 estimated National and state SCD populations based on the 2008 




derived from the National Newborn Screening Information System.  The study observed 
that National SCD population estimates ranged from 104,000 to 138,900, with a mean 
estimate of 119,100, based on birth-cohort disease prevalence.  The prevalence of SCD 
was estimated to be one in 391 persons, or 2.55 cases per thousand population.  While 
our estimate is lower compared to Hassell 2010, the reasons may be due to difference in 
data sample and methodology adopted by both the studies.  Hassell calculated the number 
of individuals with SCD by multiplying population estimates determined by the 2008 
U.S.  Census to reported or derived birth cohort-SCD prevalence from sources such as 
Agency for Health Care Policy and Research, California Screening Program and National 
Newborn Screening Information Systems (NNSIS).  Whereas we used multi-state 
Medicaid database to estimate one year prevalence of SCD.  Further, NNSIS provides 
data on birth cohort prevalence of SCD, which fails to correct for early mortality 
associated in persons with SCD, whereas our prevalence estimates included all individual 
that were alive during the enrolled study period.  Additionally, not all states in U.S 
participate in NNSIS data collection process, therefore limiting generalizability of 
prevalence estimate.  Further, the estimates provided by Hassell included only the most 
prevalent SCD genotypes and failed to incorporate rarer SCD genotypes, whereas no 
such exclusion criteria was established in our study while estimating prevalence of SCD.  
Hassell also excluded populations other than blacks and Hispanics, whereas our study 
included all available persons with SCD, irrespective of their race. 
Overall, the findings on prevalence of SCD may help in understanding disease 
epidemiology relative to other diseases, and may inform decisions for budget allocation 




epidemiological data regarding SCD may be useful for patient advocacy groups to 
provide current disease-related information to patients, payers and providers, and also in 
attempts to raise awareness regarding the disease.  
All-Cause Resource Utilization 
Sample Characteristics 
 
Out of 5,136,748 persons enrolled during the 12-month period from January 1, 
2012 through December 31, 2012, there were 8,652 individuals who had a diagnosis for 
SCD.  The individuals with an SCD diagnosis were linked one-to-one with 8,652 
individuals without SCD.  The final sample size for determining all-cause health care 
resource utilization was 17,304.  The sample was 55 percent female, with a mean age ± 
standard deviation of 21.86 ± 17.06.  Approximately 50 percent were below 19 years old.  
A significantly higher proportion of individuals in the SCD group had Charlson 
Comorbidity Index scores greater than zero (47.91 percent versus 21.4 percent, p<0.05).  
Out of 8,652 persons with SCD, 4,972 had a sickle cell crisis.  
Unadjusted Annual Health Care Resource Utilization 
 
Mean annual unadjusted hospitalizations among individuals with SCD were 1.39 
(95 percent C.I.: 1.34 to 1.45).  Our finding is similar to reports from prior studies 
assessing average hospitalizations per person per year with SCD.  While Brousseau et al. 
2010 assessing acute care utilization and re-hospitalizations in persons with SCD reports 
an average of 1.52 hospitalizations per person per year (D. C. Brousseau et al. 2010), 




Carroll et al. 2009).  Kauf et al. assessing health care resource utilization and 
expenditures in Florida Medicaid enrollees reports an average of 1.52 hospitalizations per 
person per year (Teresa L. Kauf et al. 2009), whereas Lanzkron et al. 2006 reports 1.102 
average hospitalizations per person per year (S. Lanzkron et al. 2006) and Wolfson et al. 
2011 reports an average of 1.85 hospitalizations per person per year ( J. A. Wolfson et al. 
2011).    
Mean annual unadjusted hospital days among individuals with SCD were 7.04 (95 
percent C.I.: 6.68 to 7.4) which is consistent with prior study reports (H. Davis, R. M. 
Moore, Jr., and P. J. Gergen 1997, A. K. Dickerson et al. 2012, Teresa L. Kauf et al. 
2009, S. Lanzkron et al. 2006, M. L. Mayer, T. R. Konrad, and C. C. Dvorak 2003, M. 
Mvundura et al. 2009, P. J. Nietert et al. 1999, M. J. Okumura et al. 2006, J. A. Panepinto 
et al. 2005, J. L. Raphael et al. 2009, W. C. Wang et al. 2013, K. Woods et al. 1997).  
Mean annual unadjusted emergency room visits among individuals with SCD 
were 3.71 (95 percent C.I.: 3.52 to 3.90).  While, Mvundara et al., assessing health care 
resource utilization and expenditure in persons with SCD in US reports 2.40 emergency 
room visits per person per year, Wolfson et al. 2011 reported an average of 4.53 
emergency room visits per year in person with SCD (S. L. Boulet et al. 2010, D. C. 
Brousseau et al. 2010, M. J. Frei-Jones, J. J. Field, and M. R. DeBaun 2009, Teresa L. 
Kauf et al. 2009, M. Mvundura et al. 2009, J. A. Wolfson et al. 2011). 
Incremental Annual Health Care Resource Utilization Associated with SCD 
 
The sample of 17,304 persons used to determine all-cause health care resource 
utilization was also used for estimation of incremental resource utilization associated 




(0.37), p<0.05 incremental outpatient visits compared to individuals without SCD.  
Although SCD was associated with incrementally more hospitalizations, 1.38 (0.05), 
p<0.05, the impact of SCD on hospital resource utilization is better reflected in the mean 
incremental hospital days, 6.94 (0.29), p<0.05.  Emergency room visits were also 
incrementally greater among persons with SCD, 2.66 (0.08), p<0.05.   
To our knowledge, no study assessed incremental health care resource utilization 
associated with SCD.   
Sub-Group Analysis by whether Diagnosed with Sickle Cell Crisis 
 
Among 8,652 persons with SCD, 4,972 had a diagnosis of Sickle Cell Crisis and 
3,680 persons with SCD had no diagnosis of Sickle Cell Crisis.  Significant higher, mean 
hospitalizations, 2.17, p<0.05 and hospital days, 10.98, p<0.05, emergency room visits, 
5.28, p<0.05, and outpatient visits, 26.12, p<0.05 were associated with SCD in the sub-
group with Sickle Cell Crisis.  While no study characterizes the health care resource 
utilization in persons with Sickle Cell Crisis, our findings are consistent with the 
literature in reporting that among persons with Sickle Cell Disease, the sub group of 
persons with Sickle Cell Crisis have a higher health care resource utilization as compared 
to persons without Sickle Cell Crisis. (D. C. Brousseau et al. 2010, S. D. Candrilli et al. 
2011, A. K. Dickerson et al. 2012, P. Houston-Yu et al. 2003, O. S. Platt et al. 1994, M. 
J. Frei-Jones et al. 2008, K. Woods et al. 1997, Y. M. Yang et al. 1995, E. R. Gonzalez et 
al. 1991, C. V. Pollack, Jr., D. Y. Sanders, and H. W. Severance, Jr. 1991, J. Leschke et 
al. 2012, J. L. Raphael et al. 2013, H. R. Yusuf et al. 2010, J. A. Wolfson et al. 2011, M. 




2002, M. B. Fosdal and A. W. Wojner-Alexandrov 2007, K. Frush, R. E. Ware, and T. R. 
Kinney 1995, W. R. Smith et al. 2008, N. Kunkel et al. 1994).       
Study Limitations 
While key advantage of Medicaid database are that they are population-based, and 
are not subject to recall bias, some of the limitations may include erroneous or fraudulent 
coding, lack of biomedical measures, and disease specific symptoms (severity, duration 
and frequency of Sickle Cell Crisis).  We did not separate the analyses by sickle cell 
genotype because the types of SCD may not be reliably coded in claims data.  These 
utilization estimates are almost certainly underestimates for persons with Hb SS.  
Additionally, because the states from which the Medicaid sample was drawn were not 
identified, we could not explore how eligibility requirements or covered services affected 
utilization.  Further, Medicaid sample is not necessarily representative of the national 
Medicaid population.    
Despite the difficulties inherent in the analysis of claims based data in general, 
and Medicaid data in particular, Medicaid claims are an excellent vehicle to study  
resource use associated with SCD for several reasons.  Medicaid programs provide 
comprehensive coverage for most types of medical services, thereby yielding a more 
complete analysis of medical care use.  In addition, a high proportion of patients with 
SCD are eligible for and enrolled in Medicaid programs (D.D. Amendah et al. 2010 and 





Prevalence of SCD in a Medicaid population was one in 594 persons or 1,684 
cases per million population.  The study findings indicate that SCD is associated with 
significant incremental health care resource utilization and even after adjusting for age, 
gender, race, Medicare coverage, and co-morbidities.  Incremental resource utilization 
(standard error) from outpatient visits were large, 7.27 (0.37).  Significant incremental 
resource utilization associated with SCD for hospitalizations, 1.38 (0.05), hospital days, 
6.94 (0.29) and emergency room visits, 2.66 (0.08) was also found.     
Sub-group analysis of health care resource utilization by whether diagnosed with 
Sickle Cell Crisis revealed substantially higher burden for patients with SCD and Crisis.  
These findings indicate that considerable illness burden is associated with Sickle Cell 
Crisis.   
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All-Cause Resource Utilization by Gender, and race 
Table A 1.  Unadjusted Annual Health Care Resource Utilization among Persons with 
SCD by Gender 
 ______________________________________________________________________  
   Female Male 
   (N=4,728) (N=3,924) 
  ____________________   ____________________  
   Mean Mean 
Utilization Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Hospitalizations 1.44 1.33  
   (1.36 to 1.52) (1.26 to 1.41) 
 
Hospital days 7.61 6.35  
   (7.09 to 8.13) (5.88 to 6.83) 
  
Outpatient visits 26.18 23.10 
   (25.01 to 27.34) (21.86 to 24.22) 
  
Emergency room visits 3.88 3.50 








Table A 2.  Unadjusted Annual Health Care Resource Utilization among Persons with 
SCD by Race 
 ______________________________________________________________________  
   Blacks Others 
   (N=6,401) (N=2,251) 
  ____________________   ____________________  
   Mean Mean 
Utilization Category (95% CI) (95% CI) 
 ______________________________________________________________________  
Hospitalizations 1.44 1.25  
   (1.37 to 1.51) (1.16 to 1.33) 
 
Hospital days 7.47 5.83  
   (7.03 to 7.90) (5.25 to 6.41) 
  
Outpatient visits 25.60 22.34 
   (24.57 to 26.64) (21.07 to 23.60) 
  
Emergency room visits 4.07 2.70 
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